Y0001442
N-[(cis-4-Isopropylcyclohexyl)-carbonyl]-D-phenylalanin
European Pharmacopoeia (EP) Reference Standard
Synonym(e):
N-[[cis-4-(1-Methylethyl)-cyclohexyl]-carbonyl]-D-phenylalanin
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empirische Formel (Hill-System):
C19H27NO3
CAS-Nummer:
Molekulargewicht:
317.42
UNSPSC-Code:
41116107
NACRES:
NA.24
Qualität
pharmaceutical primary standard
API-Familie
nateglinide
Hersteller/Markenname
EDQM
Anwendung(en)
pharmaceutical (small molecule)
Format
neat
Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich
Allgemeine Beschreibung
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Anwendung
N-[(cis-4-Isopropylcyclohexyl)carbonyl]-ᴅ-phenylalanine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Verpackung
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Sonstige Hinweise
Sales restrictions may apply.
Ähnliches Produkt
Produkt-Nr.
Beschreibung
Preisangaben
Lagerklassenschlüssel
11 - Combustible Solids
WGK
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Hier finden Sie alle aktuellen Versionen:
Analysenzertifikate (COA)
Lot/Batch Number
Leider sind derzeit keine COAs für dieses Produkt online verfügbar.
Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
E Phielix et al.
Diabetes, obesity & metabolism, 15(10), 915-922 (2013-04-12)
Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here, we examined whether pioglitazone plus nateglinide (PIO) interferes with hepatocellular lipid (HCL) content and/or improves insulin sensitivity in well-controlled non-obese patients with type 2 diabetes mellitus (T2DM). Sixteen patients [body mass
Ranee Chatterjee et al.
American journal of hypertension, 26(6), 723-726 (2013-02-19)
Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium. We analyzed data from the Nateglinide
F Zheng et al.
Journal of endocrinological investigation, 36(7), 489-496 (2013-01-18)
Recent studies highlight an important role of ghrelin in glucose homeostasis, while the association between ghrelin regulation and glucose fluctuation is unclear. We compared the effects of two postprandial hypoglycemic agents on ghrelin response and determined the contribution of ghrelin
Jin-Kui Yang et al.
Clinical drug investigation, 33(3), 185-191 (2013-01-23)
Diabetes mellitus has become a major public health problem in China. This open-label, prospective, multicentre, post-marketing surveillance study was conducted to investigate the efficacy and safety of nateglinide in combination with metformin in Chinese patients with type 2 diabetes (T2DM).
Subhash S Vaghani et al.
Current drug delivery, 9(6), 628-636 (2012-03-29)
In current research, chitosan was reacted with mono-chloroacetic acid under alkaline condition to prepare carboxymethyl chitosan (CMCTs). The degree of substitution (Ds) on prepared CMCTs was found to be 0.68. CMCTs was used as a potential carrier for pH specific
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.